Recent update on anti-dengue drug discovery

Eur J Med Chem. 2019 Aug 15:176:431-455. doi: 10.1016/j.ejmech.2019.05.010.

Satish N Dighe ¹, O'mezie Ekwudu ², Kamal Dua ³, Dinesh Kumar Chellappan ⁴, Peter L Katavic ², Trudi A Collet ²

Affiliations

1 Innovative Medicines Group, Institute of Health & Biomedical Innovation, School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia. Electronic address: sdighe2008@gmail.com.
2 Innovative Medicines Group, Institute of Health & Biomedical Innovation, School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia.
3 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Australia.
4 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur, 57000, Malaysia.

PMID: 31128447 DOI: 10.1016/j.ejmech.2019.05.010

Abstract

Dengue is the most important arthropod-borne viral disease of humans, with more than half of the global population living in at-risk areas. Despite the negative impact on public health, there are no Antiviral therapies available, and the only licensed vaccine, Dengvaxia^®, has been contraindicated in children below nine years of age. In an effort to combat dengue, several small molecules have entered into human clinical trials. Here, we review anti-DENV molecules and their drug targets that have been published within the past five years (2014-2018). Further, we discuss their probable mechanisms of action and describe a role for classes of clinically approved drugs and also an unclassified class of anti-DENV agents. This review aims to enhance our understanding of novel agents and their cognate targets in furthering innovations in the use of small molecules for dengue drug therapies.

Keywords

DENV; Dengue; HTS; HTVS; NS3; NS4; NS5; Natural product; Synthesis.

Name
Email *

	Sorry, but the email address you supplied was invalid.